MedTrace Logo

HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)

NCT06084559 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-16

No results posted yet for this study

Summary

To study the effect of SOT in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live \>2500m on pulmonary artery pressure (PAP) and other hemodynamics by echocardiography and in relation to blood gases at 2840m with and without SOT.

Conditions

  • Pulmonary Vascular Disorder
  • Pulmonary Artery Hypertension
  • Chronic Thromboembolic Pulmonary Hypertension

Interventions

OTHER

Supplemental oxygen therapy

Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied

OTHER

Sham Oxygen therapy

Patients will reveice pressurized air via a nasal cannula

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Silvia Ulrich, Prof. Dr. · University Hospital Zurich, Departement of Pulmonology

  • Rodrigo Hoyos, Dr. · Carlos Adrade Marin Hospital of Quito, Equador

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-05
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06084559 on ClinicalTrials.gov